Showing results (1061-1070 of 1,273) with videos related to
Sort By:
Pageof 128
BMC Neurology|October 7, 2020
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosisGiancarlo Comi, Mark S Freedman, José E Meca-Lallana, et al.Anti-Cancer Drugs|August 1, 1997
A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinomaA P Kudelka, Z H Siddik, D Tresukosol, et al.Anti-Cancer Drugs|June 23, 1999
A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancerC F Verschraegen, E Gupta, E Loyer, et al.Anti-Cancer Drugs|September 1, 1996
Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-alpha and 13-cis-retinoic acid: report of two cases and review of the literatureS Piamsomboon, W Termrungruanglert, A P Kudelka, et al.Journal of Neurology|January 14, 2014
Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX studyMark S Freedman, Nicola De Stefano, Frederik Barkhof, et al.Pediatric Obesity|January 22, 2022
Measuring BMI change among children and adolescentsDavid S Freedman, Amy J Goodwin Davies, Thao-Ly Tam Phan, et al.Cancers|November 25, 2018
ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer ProgressionTsz-Lun Yeung, Ching Chou Tsai, Cecilia S Leung, et al.Cellular Immunology|July 26, 2005
Substantial proportions of identical beta-chain T-cell receptor transcripts are present in epithelial ovarian carcinoma tumorsJohn Pappas, Weon-Ju Jung, Angeliki K Barda, et al.Journal of Neurology, Neurosurgery, and Psychiatry|December 3, 2013
Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromesNicola De Stefano, Giancarlo Comi, Ludwig Kappos, et al.Elife|May 14, 2024
Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitorsDamien M Rasmussen, Manny M Semonis, Joseph T Greene, et al.Pageof 128